Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Katrin P. Guillen"'
Autor:
Sandra D. Scherer, Ling Zhao, Andrew J. Butterfield, Chieh-Hsiang Yang, Emilio Cortes-Sanchez, Katrin P. Guillen, Bryan E. Welm, Alana L. Welm
Publikováno v:
STAR Protocols, Vol 4, Iss 3, Pp 102402- (2023)
Summary: Patient-derived xenografts (PDXs) have clinical value but are time-, cost-, and labor-intensive and thus ill-suited for large-scale experiments. Here, we present a protocol to convert PDX tumors into PDxOs for long-term cultures amenable to
Externí odkaz:
https://doaj.org/article/caabe65db8564dada1e80756fb6070c9
Autor:
Blake R. Wilde, Mohan R. Kaadige, Katrin P. Guillen, Andrew Butterfield, Bryan E. Welm, Donald E. Ayer
Publikováno v:
Cancer & Metabolism, Vol 8, Iss 1, Pp 1-13 (2020)
Abstract Background Protein synthesis is regulated by the availability of amino acids, the engagement of growth factor signaling pathways, and adenosine triphosphate (ATP) levels sufficient to support translation. Crosstalk between these inputs is ex
Externí odkaz:
https://doaj.org/article/c974fd6b85e94429a1a2e9d12bfd477a
Autor:
Jeffery M. Vahrenkamp, Chieh-Hsiang Yang, Adriana C. Rodriguez, Aliyah Almomen, Kristofer C. Berrett, Alexis N. Trujillo, Katrin P. Guillen, Bryan E. Welm, Elke A. Jarboe, Margit M. Janat-Amsbury, Jason Gertz
Publikováno v:
Cell Reports, Vol 22, Iss 11, Pp 2995-3005 (2018)
Summary: Steroid hormone receptors are simultaneously active in many tissues and are capable of altering each other’s function. Estrogen receptor α (ER) and glucocorticoid receptor (GR) are expressed in the uterus, and their ligands have opposing
Externí odkaz:
https://doaj.org/article/373a73b79ed044d69306f26432b18e84
Autor:
Jason Gertz, Barbara J. Graves, Margit M. Janát-Amsbury, Bryan E. Welm, Chieh-Hsiang Yang, Sandra D. Scherer, Katrin P. Guillen, Kathleen A. Clark, Kristofer C. Berrett, Jeffery M. Vahrenkamp, Adriana C. Rodriguez
SF1: ETV4 expression levels in endometrial cancer. SF2: Expression levels of ETV4 in candidate knockout clones. SF3: Short-term knockdown of ETV4 reduces ER genomic binding. SF4: Validation of rescue and overexpression of ETV4. SF5: Estrogen induced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20fca2f95362a815a5d7fe76da38aef1
https://doi.org/10.1158/0008-5472.22424760.v1
https://doi.org/10.1158/0008-5472.22424760.v1
Autor:
Jason Gertz, Barbara J. Graves, Margit M. Janát-Amsbury, Bryan E. Welm, Chieh-Hsiang Yang, Sandra D. Scherer, Katrin P. Guillen, Kathleen A. Clark, Kristofer C. Berrett, Jeffery M. Vahrenkamp, Adriana C. Rodriguez
Estrogen signaling through estrogen receptor alpha (ER) plays a major role in endometrial cancer risk and progression, however, the molecular mechanisms underlying ER's regulatory role in endometrial cancer are poorly understood. In breast cancer cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c44e4c068cc19c3774e56c196660b729
https://doi.org/10.1158/0008-5472.c.6511863.v1
https://doi.org/10.1158/0008-5472.c.6511863.v1
Autor:
Katrin P. Guillen, Maihi Fujita, Andrew J. Butterfield, Sandra D. Scherer, Matthew H. Bailey, Zhengtao Chu, Yoko S. DeRose, Ling Zhao, Emilio Cortes-Sanchez, Chieh-Hsiang Yang, Jennifer Toner, Guoying Wang, Yi Qiao, Xiaomeng Huang, Jeffery A. Greenland, Jeffery M. Vahrenkamp, David H. Lum, Rachel E. Factor, Edward W. Nelson, Cindy B. Matsen, Jane M. Poretta, Regina Rosenthal, Anna C. Beck, Saundra S. Buys, Christos Vaklavas, John H. Ward, Randy L. Jensen, Kevin B. Jones, Zheqi Li, Steffi Oesterreich, Lacey E. Dobrolecki, Satya S. Pathi, Xing Yi Woo, Kristofer C. Berrett, Mark E. Wadsworth, Jeffrey H. Chuang, Michael T. Lewis, Gabor T. Marth, Jason Gertz, Katherine E. Varley, Bryan E. Welm, Alana L. Welm
Publikováno v:
Nature Cancer. 3:232-250
Models that recapitulate the complexity of human tumors are urgently needed to develop more effective cancer therapies. We report a bank of human patient-derived xenografts (PDXs) and matched organoid cultures from tumors that represent the greatest
Autor:
Elizabeth Benner, Emilio Cortes-Sanchez, Carol A. Lange, Carlos Perez Kerkvliet, Camila O. dos Santos, Thomas Pengo, Chieh Hsiang Yang, Katrin P. Guillen, Sucheta Telang, Thu H. Truong, Ying Wang, Nuri A. Temiz, Marygrace C. Trousdell, Bryan E. Welm, Kyla M. Hagen, Julie H. Ostrander
Publikováno v:
Oncogene
Recurrence of metastatic breast cancer stemming from acquired endocrine and chemotherapy resistance remains a health burden for women with luminal (ER+) breast cancer. Disseminated ER+ tumor cells can remain viable but quiescent for years to decades.
Autor:
James Turkson, Peibin Yue, Katherine E. Varley, Joy M. McDaniel, Stephanie L. Parker, Donald J. Buchsbaum, Bryan E. Welm, Katrin P. Guillen, Richard M. Myers, Patsy G. Oliver, Megan E. Conway, James M. Graham
Publikováno v:
Cancer Res
Breast cancers are divided into subtypes with different prognoses and treatment responses based on global differences in gene expression. Luminal breast cancer gene expression and proliferation are driven by estrogen receptor alpha, and targeting thi
Autor:
Sandra D. Scherer, Chieh-Hsiang Yang, Adriana C. Rodriguez, Jeffery M. Vahrenkamp, Jason Gertz, Katrin P. Guillen, Kristofer C. Berrett, Kathleen A. Clark, Barbara J. Graves, Margit M. Janát-Amsbury, Bryan E. Welm
Publikováno v:
Cancer Res
Estrogen signaling through estrogen receptor alpha (ER) plays a major role in endometrial cancer risk and progression, however, the molecular mechanisms underlying ER's regulatory role in endometrial cancer are poorly understood. In breast cancer cel
Autor:
Mona Foth, Courtney C. Cavalieri, Lance D. Burrell, Stephanie L. Cutler, Conan G. Kinsey, Kajsa E. Affolter, Jill E. Shea, Amelie M. Boespflug, Kaitrin M. Rehbein, Alana L. Welm, Jeffrey T. Yap, Bryan E. Welm, Michael T. Seipp, Sophia S. Schuman, Jonathan Whisenant, G. Weldon Gilcrease, Amanda Truong, David H. Lum, Katrin P. Guillen, Courtney L. Scaife, Martin McMahon, Eric L. Snyder, Soledad A. Camolotto
Publikováno v:
Nature medicine
Pancreatic ductal adenocarcinoma (PDA) was responsible for ~ 44,000 deaths in the United States in 2018 and is the epitome of a recalcitrant cancer driven by a pharmacologically intractable oncoprotein, KRAS1–4. Downstream of KRAS, the RAF→MEK→